<li>eliglustat<p>paroxetine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive  and intermediate metabolizers;  eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.</p></li><li>isocarboxazid<p>isocarboxazid and paroxetine both increase  serotonin levels. Contraindicated.</p></li><li>phenelzine<p>phenelzine and paroxetine both increase  serotonin levels. Contraindicated.</p></li><li>pimozide<p>paroxetine increases levels of pimozide by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Contraindicated. Coadministration increases pimozide AUC and Cmax and may result in prolonged QT interval.</p></li><li>procarbazine<p>procarbazine and paroxetine both increase  serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use.</p></li><li>selegiline<p>selegiline and paroxetine both increase  serotonin levels. Contraindicated. At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug.</p></li><li>thioridazine<p>paroxetine increases levels of thioridazine by decreasing metabolism. Contraindicated. Risk of long QT syndrome.</p></li><li>tranylcypromine<p>tranylcypromine and paroxetine both increase  serotonin levels. Contraindicated.</p></li>